Nov 27 (Reuters) - Benitec Biopharma Ltd BLT.AX :
* BENITEC BIOPHARMA PROVIDES UPDATE ON OPMD ORPHAN DISEASE PROGRAM
* BENITEC BIOPHARMA - SUBMITTED APPLICATION WITH U.S. FDA SEEKING ORPHAN DRUG DESIGNATION FOR BB-301 AS A TREATMENT OF OCULOPHARYNGEAL MUSCULAR DYSTROPHY
* SAYS INTENDS TO FILE AN IND FOR BB-301 IN Q4 OF CALENDAR YEAR 2018